Mineralys Therapeutics, Inc. - Common Stock — Quarterly Cash Flow (NASDAQ:MLYS) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Total assets 354.94 M335.72 M599.95 M661.81 M652.86 M Total liabilities 13.39 M22.17 M23.52 M15.11 M14.72 M Total equity 341.56 M313.55 M576.43 M646.69 M638.14 M Total liabilities & shareholders' equities 354.94 M335.72 M599.95 M661.81 M652.86 M Total debt ————— Net debt —————

News

Mineralys Therapeutics, Inc. (MLYS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Mineralys Therapeutics, Inc. (MLYS) Presents at 35th European Meeting on Hypertension and Cardiovascular Protection - Slideshow (NASDAQ:MLYS) 2026-06-01

Mineralys Therapeutics, Inc. (MLYS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Jefferies cuts Mineralys Therapeutics price target on drug concerns

Mineralys: Big Pharma Threatens To Undermine Likely Hypertension Drug Approval (MLYS)

Stifel reiterates Buy rating on Mineralys stock, $52 target

BofA raises Mineralys Therapeutics stock price target on NDA progress

Mineralys Therapeutics, Inc. (MLYS) Q4 2025 Earnings Call Transcript

Mineralys earnings in focus as FDA lorundrostat decision looms

Mineralys Stock Rises as FDA Accepts NDA for Hypertension Drug

Stifel reiterates Mineralys Therapeutics stock rating on lorundrostat data

H.C. Wainwright reiterates Mineralys stock rating on FDA acceptance